Screening of potential molecular targets for colorectal cancer therapy

International Journal of General Medicine

Volumn 2, Issue , 2009, Pages 243-257

  Honma, Kimi ^a   Takemasa, Ichiro ^b   Matoba, Ryo ^c   Yamamoto, Yusuke ^a   Takeshita, Fumitaka ^b   Mori, Masaki ^b   Monden, Morito ^b   Matsubara, Kenichi ^c   Ochiya, Takahiro ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c DNA CHIP RESEARCH INC   (Japan)

Author keywords

Colorectal cancer; Molecular target; PSMA7; RAN; RNAi

Indexed keywords

PROTEASOME; PROTEASOME PSMA 7; RAN PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER TISSUE; COLON; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG SCREENING; FEMALE; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER METASTASIS; LUNG METASTASIS; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEOTIDE SEQUENCE; TUMOR XENOGRAFT; UNINDEXED SEQUENCE;

EID: 77953439716     PISSN: None     EISSN: 11787074     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Garcia M, Jemal A, Ward EM, et al. Global Cancer Facts and Figures 2007. Atlanta, GA: American Cancer Society, 2007. p. 12-14.
2. National Cancer Center. Tokyo, Japan. Cancer statistics in Japan (2008). Available from http://ganjoho.ncc.go.jp/public/statistics/ backnumber/2008-en. html. Accessed July 2, 2009.
3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100(1):57-70.
4. Baranda J, Williamson S. The new paradigm in the treatment of colorectal cancer: are we hitting the right target? Expert Opin Investig Drugs. 2007;16(3):311-324.
5. Köhne CH, Lenz HJ. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. Oncologist. 2009;14(5):478-488.
6. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438(7070):967-974.
7. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362(6423):841-844.
8. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-2342.
9. Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000;60(8):2178-2189.
10. Drevs J, Hofmann I, Hugenschmidt H, et al. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res. 2000;60(17):4819-4824.
11. Mellinghoff I. Why do cancer cells become "addicted" to oncogenic epidermal growth factor receptor? PLoS Med. 2007;4(10):1620-1622.
12. Henson ES, Gibson SB. Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy. Cell Signal. 2006;18(12):2089-2097.
13. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337-345.
14. Saltz L, Easley C, Kirkpatrick P. Panitumumab. Nat Rev Drug Discov. 2006;5(12):987-988.
15. Taylor K, Micha D, Ranson M, Dive C. Recent advances in targeting regulators of apoptosis in cancer cells for therapeutic gain. Expert Opin Investig Drugs. 2006;15(6):669-690.
16. Frenzel A, Grespi F, Chmelewskij W, Villunger A. Bcl2 family proteins in carcinogenesis and the treatment of cancer. Apoptosis. 2009;14(4):584-596.
17. Klasa RJ, Gillum AM, Klem RE, Frankel SR. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev. 2002;12:193-213.
18. Newsom-Davis T, Prieske S, Walczak H. Is TRAIL the holy grail of cancer therapy? Apoptosis. 2009;14(4):607-623.
19. Marini P, Denzinger S, Schiller D, et al. Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dosedependent growth delay in vivo. Oncogene. 2006;25(37):5145-5154.
20. Honma K, Iwao-Koizumi K, Takeshita F, et al. RPN2 gene confers docetaxel resistance in breast cancer. Nat Med. 2008;14(9):939-948.
21. Komori T, Takemasa I, Yamasaki M, et al. Gene expression of colorectal cancer: preoperative genetic diagnosis using endoscopic biopsies. Int J Oncol. 2008;32(2):367-375.
22. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411(6836):494-498.
23. Gerards WL, de Jong WW, Boelens W, Bloemendal H. Structure and assembly of the 20S proteasome. Cell Mol Life Sci. 1998;54(3):253-262.
24. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell. 2004;5(5):417-421.
25. Huang J, Kwong J, Sun EC, Liang TJ. Proteasome complex as a potential cellular target of hepatitis B virus X protein. J Virol. 1996;70(8): 5582-5591.
26. Krüger M, Beger C, Welch PJ, Barber JR, Manns MP, Wong-Staal F. Involvement of proteasome alpha-subunit PSMA7 in hepatitis C virus internal ribosome entry site-mediated translation. Mol Cell Biol. 2001;21(24):8357-8364.
27. Hoeller D, Dikic I. Targeting the ubiquitin system in cancer therapy. Nature. 2009;458(7237):438-444.
28. Karin M. Nuclear factor-B in cancer development and progression. Nature. 2006;441(7092):431-436.
29. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Proteasome inhibition in the treatment of cancer. Cell Cycle. 2005;4(2):290-296.
30. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitinproteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell. 1994;78(5): 773-785.
31. Cusack JC Jr, Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 2001;61(9):3535-3540.
32. Pitts TM, Morrow M, Kaufman SA, Tentler JJ, Eckhardt SG. Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models. Mol Cancer Ther. 2009;8(2):342-349.
33. Voortman J, Giaccone G. Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. BMC Cancer. 2006;6:129.
34. Perfetti V, Palladini G, Brunetti L, et al. Bortezomib-induced paralytic ileus is a potential gastrointestinal side effect of this first-in-class anticancer proteasome inhibitor. Eur J Gastroenterol Hepatol. 2007;19(7):599-601.
35. Hu XT, Chen W, Wang D, et al. The proteasome subunit PSMA7 located on the 20q13 amplicon is overexpressed and associated with liver metastasis in colorectal cancer. Oncol Rep. 2008;19(2):441-446.
36. Kuersten S, Ohno M, Mattaj IW. Nucleocytoplasmic transport: Ran, beta and beyond. Trends Cell Biol. 2001;11(12):497-503.
37. Pemberton LF, Paschal BM. Mechanisms of receptor-mediated nuclear import and nuclear export. Traffic. 2005;6(3):187-198.
38. Joseph J. Ran at a glance. J Cell Sci. 2006;119(Pt 17):3481-3484.
39. Hetzer M, Gruss OJ, Mattaj IW. The Ran GTPase as a marker of chromosome position in spindle formation and nuclear envelope assembly. Nat Cell Biol. 2002;4(7):E177-E184.
40. Woo IS, Jang HS, Eun SY, et al. Ran suppresses paclitaxel-induced apoptosis in human glioblastoma cells. Apoptosis. 2008;13(10):1223-1231.
41. Xia F, Lee CW, Altieri DC. Tumor cell dependence on Ran-GTP-directed mitosis. Cancer Res. 2008;68(6):1826-1833.
42. Morgan-Lappe SE, Tucker LA, Huang X, et al. Identification of Ras-related nuclear protein, targeting protein for xenopus kinesin-like protein 2, and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screen. Cancer Res. 2007;67(9):4390-4398.